|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004.
|
|
3
|
Peaz JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004.
|
|
4
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009.
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, et al:
North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010.
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, et al:
West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harboring
mutations of the epidermal growth factor receptor (WJTOG3405): an
open label, randomized phase 3 trial. Lancet Oncol. 11:121–128.
2010.
|
|
7
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase
3 study. Lancet Oncol. 12:735–742. 2011.
|
|
8
|
Rosell R, Carcereny E, Gervais R, et al:
Spanish Lung Cancer Group in collaboration with Groupe Français de
Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica:
Erlotinib versus chemotherapy as first-line treatment for patients
with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): a multicenter, open-label, randomized, phase 3 trial.
Lancet Oncol. 13:239–246. 2012.
|
|
9
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: National Cancer Institute of Canada Clinical Trials
Group: Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med. 353:123–132. 2005.
|
|
10
|
Ciuleanu T, Stelmakh L, Cicenas S, et al:
Efficacy and safety of erlotinib versus chemotherapy in second-line
treatment of patients with advanced, non-small-cell lung cancer
with poor prognosis (TITAN): a randomised multicentre, open-label,
phase 3 study. Lancet Oncol. 13:300–308. 2012.
|
|
11
|
Walleser S, Ray J, Bischoff H, et al:
Maintenance erlotinib in advanced nonsmall cell lung cancer:
cost-effectiveness in EGFR wild-type across Europe. Clinicoecon
Outcomes Res. 4:269–275. 2012.
|
|
12
|
Wu SG, Hu FC, Chang YL, et al: Frequent
EGFR mutations in nonsmall cell lung cancer presenting with miliary
intrapulmonary carcinomatosis. Eur Respir J. 41:417–424. 2013.
|
|
13
|
Wu SG, Yu CJ, Tsai MF, et al: Survival of
lung adenocarcinoma patients with malignant pleural effusion. Eur
Respir J. 41:1409–1418. 2013.
|
|
14
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
|
|
15
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982.
|
|
16
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
|
|
17
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005.
|
|
18
|
Wacker B, Nagrani T, Weinberg J, et al:
Correlation between development of rash and efficacy in patients
treated with the epidermal growth factor receptor tyrosine kinase
inhibitor erlotinib in two large phase III studies. Clin Cancer
Res. 13:3913–3921. 2007.
|
|
19
|
Liu HB, Wu Y, Lv TF, et al: Skin Rash
could predict the response to EGFR tyrosine kinase inhibitor and
the prognosis for patients with non-small cell lung cancer: a
systematic review and meta-analysis. PLoS One. 8:e551282013.
|
|
20
|
Moyer JD, Barbacci EG, Iwata KK, et al:
Induction of apoptosis and cell cycle arrest by CP-358,774, an
inhibitor of epidermal growth factor receptor tyrosine kinase.
Cancer Res. 57:4838–4848. 1997.
|
|
21
|
Pollack VA, Savage DM, Baker DA, et al:
Inhibition of epidermal growth factor receptor-associated tyrosine
phosphorylation in human carcinoma with CP-358, 774: dynamics of
receptor inhibition in situ and antitumor effects in athymic mice.
J Pharmacol Exp Ther. 291:739–748. 1999.
|
